RxDoctor Payments Data

Bret Cuthbertson, MD

Internal Medicine · Auburn, ALNPI 1104808088

Payments from drug & device makers

$4,598in general payments, 2019–2025

Across 279 payments — averaging $16.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$334
  • Tris Pharma Inc$333
  • Corium, LLC$306
  • AstraZeneca$271
  • Lilly USA, LLC$258
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$4,598100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,598 in reported general payments places this provider in the 80th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$42,125
Medicare patients
107
Services billed
1,091

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide58$66,769
MounjaroTirzepatide36$44,228
JardianceEmpagliflozin38$30,453
FarxigaDapagliflozin Propanediol23$20,887
Janumet XrSitagliptin Phos/Metformin Hcl15$16,038
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$15,921
JanuviaSitagliptin Phosphate11$8,248
Atorvastatin Calcium297$3,215
Testosterone13$2,335
Duloxetine Hcl75$1,700
Valsartan69$1,682
Levothyroxine Sodium101$1,612
Metoprolol Succinate68$1,570
Gabapentin77$1,533
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide22$1,267

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$103$66,76958 claims
Lilly USA, LLCMounjaro$258$44,22836 claims
Boehringer IngelheimJardiance$73$30,45338 claims
MerckJanumet Xr, Januvia$136$24,28626 claims
AstraZenecaFarxiga$271$20,88723 claims
GSKTrelegy Ellipta$47$15,92125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Auburn

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →